Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Yellow Fever Virus Infection" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A disease caused by infection with the yellow fever virus, which is carried by mosquitos. Symptoms include body aches, chills, fever, severe headache, weakness, and a yellow skin color. Bleeding, vomiting, and failure of the liver and other organs may occur in late stages of the disease.
High yield yellow fever virus strain with increased propagation in cells
ActiveUS20110287519A1High yieldSpread the wordSsRNA viruses positive-senseViral antigen ingredientsYellow Fever Virus InfectionViral infection
The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
Owner:PNUVAX INC
DNA molecule, recombinant virus and preparation method and application of DNA molecule and recombinant virus
ActiveCN107201370AFully attenuatedImprove securitySsRNA viruses positive-senseViral antigen ingredientsYellow Fever Virus InfectionStructural protein
The invention relates to the technical field of biology and discloses a DNA molecule, a recombinant virus and a preparation method and application of the DNA molecule and the recombinant virus. The DNA molecule contains a 5' noncoding region sequence, a capsid protein coding sequence, a DNA sequence, a membrane protein precursor coding sequence, an envelope protein coding sequence, a non-structural protein coding sequence and a 3' noncoding region sequence, wherein the DNA sequence corresponds to an internal ribosome entry site sequence with the 5' end connected with a termination codon sequence, and all the sequences except the DNA sequence are derived from yellow fever virus attenuated strains. The cDNA sequence corresponding to the genome RNA of the recombinant virus is identical with the sequence of the DNA molecule. The DNA molecule can be used for building the recombinant virus so as to obtain a vaccine capable of effectively preventing yellow fever virus infection.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Application of carbamazepine to preparation of medicines for treating flavivirus infection
ActiveCN108309983AImprove securityReduce mortalityAntiviralsHeterocyclic compound active ingredientsZika virusWest Nile Virus Infection
The invention discloses application of carbamazepine to preparation of medicines for treating flavivirus infection, particularly application of the carbamazepine to preparation of a medicine for treating Japanese b encephalitis virus infection, a medicine for treating Zika virus infection, a medicine for treating West Nile virus infection, a medicine for treating yellow fever virus infection and amedicine for treating 1-4 type dengue virus infection. The carbamazepine can effectively reduce the death rate of mice infected with Japanese b encephalitis virus; in addition, the carbamazepine hasbeen applied clinically for a long time and has high safety. Therefore, the carbamazepine can be further developed to serve as a medicine for treating flavivirus infection and provide new choice for clinical medication.
Owner:武汉百药联科科技有限公司
High yield yellow fever virus strain with increased propagation in cells
ActiveUS8741312B2High yieldSpread the wordSsRNA viruses positive-senseViral antigen ingredientsYellow Fever Virus InfectionViral infection
The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
Owner:PNUVAX INC
Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus
InactiveCN106983750ANo obvious toxicityHighly toxicAntiviralsHeterocyclic compound active ingredientsDiseaseZika virus
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT
High-functional-activity yellow fever virus humanized monoclonal antibody and application thereof
ActiveCN110343173AHigh affinityFree from attackBiological material analysisImmunoglobulins against virusesEscherichia coliAntigen
The present invention discloses a high-functional-activity yellow fever virus humanized monoclonal antibody and an application thereof, and belongs to the technical field of medicines. A yellow fevervirus E protein expressed by escherichia coli is used as an antigen, memory B cells specifically combined with the yellow fever virus E protein are screened from PBMCs of a case of a convalescent patient through fluorescence-activated cell sorting, then the screened single B cells are subjected to RT-PCR and PCR amplification to obtain an antibody variable region segment, and the antibody variableregion segment is further connected with a constant region into an expression vector. After mammalian cell expression and purification, a series of function detections are carried out to obtain the humanized monoclonal antibody with a function of protecting from yellow fever virus infection. The antibody has affinity with the antigen at 0.588 nM, has strong yellow fever virus neutralization activity, has IC50 at 3.7ng / ml, can completely protect mice from being attacked by yellow fever viruses with a lethal dose, and has application values of clinical treatment and prevention of the yellow fever viruses.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection
ActiveCN102872057AEffective preventionEffective therapeuticOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses application of Gypensapogenin A to preparing drugs for treating or preventing yellow fever virus infection. Gypensapogenin A is capable of effectively inhibiting the proliferation of yellow fever virus, has little toxicity to cells, can be further developed as the drugs for treating diseases caused by virus infection and has extensive application prospect. The application of Gypensapogenin A to preparing the drugs for treating the yellow fever virus infection, disclosed by the invention, is firstly published, the framework type is brand new, the activity of inhibiting the yellow fever virus is unexpectedly strong and the probability of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in preventing and treating the yellow fever virus infection is made at the same time.
Owner:南通三聚知识产权服务有限公司
Epidemic encephalitis B/yellow fever chimeric virus and preparation method and application thereof
ActiveCN105400799AAvoid infectionLow toxicitySsRNA viruses positive-senseViral antigen ingredientsYellow Fever Virus InfectionCdna cloning
The invention discloses cDNA cloning of an epidemic encephalitis B / yellow fever chimeric virus. The nucleotide sequence of the virus is as shown in SEQ ID NO.1. The invention further discloses the epidemic encephalitis B / yellow fever chimeric virus, application thereof and a vaccine preventing yellow fever. The chimeric virus Chimeri-JYF is small in toxicity and good in immune protection function. The vaccine prepared through the virus can effectively prevent yellow fever virus infection, is high in safety, can be used for replacing existing yellow fever live attenuated vaccines (17D strains), effectively improves clinical use safety while the immune protection function is guaranteed, and is good in application prospect.
Owner:CHENGDU INST OF BIOLOGICAL PROD
Application of Lycojaponicumin C in preparation of medicines for treating yellow fever virus infection
InactiveCN103463067AEffective preventionEffective therapeuticOrganic active ingredientsAntiviralsLycojaponicumin CDisease
The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating or preventing yellow fever virus infection. The Lycojaponicumin C can be used for effectively inhibiting the proliferation of yellow fever virus, has very low toxicity on cells, can be further developed into the medicines for treating diseases caused by the virus infection and has wide application prospects. The application of the Lycojaponicumin C in the preparation of medicines for treating the yellow fever virus infection is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on yellow fever virus, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin C has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing or treating the yellow fever virus infection.
Owner:重庆市黔江区阿蓬科技企业孵化器有限公司
Application of carbamazepine in preparation of medicine for treating flavivirus infection
ActiveCN108309983BImprove securityReduce mortalityAntiviralsHeterocyclic compound active ingredientsJapanese B Encephalitis VirusYellow Fever Virus Infection
The invention discloses application of carbamazepine to preparation of medicines for treating flavivirus infection, particularly application of the carbamazepine to preparation of a medicine for treating Japanese b encephalitis virus infection, a medicine for treating Zika virus infection, a medicine for treating West Nile virus infection, a medicine for treating yellow fever virus infection and amedicine for treating 1-4 type dengue virus infection. The carbamazepine can effectively reduce the death rate of mice infected with Japanese b encephalitis virus; in addition, the carbamazepine hasbeen applied clinically for a long time and has high safety. Therefore, the carbamazepine can be further developed to serve as a medicine for treating flavivirus infection and provide new choice for clinical medication.
Owner:武汉百药联科科技有限公司
Application of palmatine in medicine for treating yellow fever virus infection
InactiveCN101596193AEnhanced inhibitory effectStrengthen research and development effortsOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses an application of palmatine for preparing medicine for treating and preventing yellow fever virus infection; the inhibition ratio of palmatine to yellow fever virus (YFV) under the condition that the concentration of the palmatine is 100mu m is 96.58 percent, and the survival rate of Vero cells is 92.93 percent under the condition that the concentration of the palmatine is 100mu m. The palmatine can effectively inhibit proliferation of yellow fever virus, but has low cytotoxicity, therefore, the palmatine can be further developed into the medicine for treating diseases caused by yellow fever virus infection and has wide application prospect.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of incarviatone A in preparation of medicine for treating yellow fever virus infection
InactiveCN103462963BEnhanced inhibitory effectWide application backgroundOrganic active ingredientsAntiviralsYellow Fever Virus InfectionCytotoxicity
The invention discloses an application of Incarviatone A in medicaments for treating yellow fever virus infection. The Incarviatone A can effectively inhibit proliferation of yellow fever viruses, but has low toxicity to cells, can be further developed into the medicaments for treating diseases caused by the yellow fever virus infection, and has a wide application prospect. The application of the Incarviatone A in preparation of the medicaments for treating the yellow fever virus infection is made public for the first time, the skeleton type is completely novel, and the Incarviatone A has an unexpectedly strong yellow fever virus inhibiting activity, so the probability that other compounds give any revelation does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently possessed in prevention and treatment of the yellow fever virus infection.
Owner:刘玮 +1
Applications of Sarcaboside A in medicament for treating yellow fever virus infection
InactiveCN103446105AEffective preventionEffective therapeuticOrganic active ingredientsAntiviralsYellow Fever Virus InfectionViral infection
The invention discloses applications of Sarcaboside A in preparing a medicament for treating or preventing yellow fever virus infection. The Sarcaboside A can effectively inhibit the proliferation of yellow fever virus, and can be further developed into a medicament for treating yellow fever virus infection-caused diseases due to low cell toxicity, thus having wide application prospects. The applications of the Sarcaboside A in a medicament for treating yellow fever virus infection are disclosed for the first time. As a skeleton type of the Sarcaboside A belongs to a brand-new skeleton type, the Sarcaboside A has unexpectedly strong yellow fever virus inhibition activity, and the possibility of giving any inspiration by other compounds does not exist. The Sarcaboside A has significantly substantive characteristics, as well as obviously prominent progress in the prevention and treatment of the yellow fever virus infection.
Owner:NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECH
A kind of dna molecule and recombinant virus and their preparation method and application
ActiveCN107201370BFully attenuatedImprove securitySsRNA viruses positive-senseViral antigen ingredientsYellow Fever Virus InfectionStructural protein
The invention relates to the technical field of biology and discloses a DNA molecule, a recombinant virus and a preparation method and application of the DNA molecule and the recombinant virus. The DNA molecule contains a 5' noncoding region sequence, a capsid protein coding sequence, a DNA sequence, a membrane protein precursor coding sequence, an envelope protein coding sequence, a non-structural protein coding sequence and a 3' noncoding region sequence, wherein the DNA sequence corresponds to an internal ribosome entry site sequence with the 5' end connected with a termination codon sequence, and all the sequences except the DNA sequence are derived from yellow fever virus attenuated strains. The cDNA sequence corresponding to the genome RNA of the recombinant virus is identical with the sequence of the DNA molecule. The DNA molecule can be used for building the recombinant virus so as to obtain a vaccine capable of effectively preventing yellow fever virus infection.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Application of palmatine in medicine for treating yellow fever virus infection
InactiveCN101596193BEnhanced inhibitory effectStrengthen research and development effortsOrganic active ingredientsAntiviralsYellow Fever Virus InfectionCytotoxicity
The invention discloses an application of palmatine for preparing medicine for treating and preventing yellow fever virus infection; the inhibition ratio of palmatine to yellow fever virus (YFV) under the condition that the concentration of the palmatine is 100mu m is 96.58 percent, and the survival rate of Vero cells is 92.93 percent under the condition that the concentration of the palmatine is100mu m. The palmatine can effectively inhibit proliferation of yellow fever virus, but has low cytotoxicity, therefore, the palmatine can be further developed into the medicine for treating diseasescaused by yellow fever virus infection and has wide application prospect.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of lycopalhine A in preparation of drugs for treating or preventing yellow fever virus infections
InactiveCN105267218AStrong inhibitory activitySignificant progressOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses an application of lycopalhine A in the preparation of drugs for treating or preventing yellow fever virus infections. Lycopalhine A is effective in inhibiting the proliferation of yellow fever virus, has little toxicity on cells, can be further developed into drugs for treating diseases caused by these virus infections and has a promising application prospect. The application of the lycopalhine A in the preparation of drugs for treating yellow fever virus infections is disclosed for the first time; since its skeleton type is novel and the lycopalhine A is has unexpected activity in inhibiting yellow fever virus, chances that other compounds given any implication are zero; the lycopalhine A has outstanding substantive features and has significant progress in use for controlling the yellow fever virus infections.
Owner:ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Application of Chukrasone B in preparing medicines for treating yellow fever virus infection
InactiveCN103356603AStrong inhibitory activitySignificant progressOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses an application of Chukrasone B in preparing medicines for treating or preventing yellow fever virus infection. The Chukrasone B can effectively inhibit proliferation of yellow fever virus but is small in cytotoxicity, so that the Chukrasone B can be further developed to medicines for treating diseases caused by the virus infection, and has a wide application prospect. The use of the Chukrasone B for preparing medicines for treating yellow fever virus infection provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, and the inhibitory activity of the Chukrasone B to yellow fever virus infection is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Chukrasone B has remarkable substantial characteristics and meanwhile has a remarkable progress for preventing and treating yellow fever virus infection.
Owner:丁圣雨
Application of lycojaponicumin A in preparation of medicine for treating yellow fever virus infection
ActiveCN103446137BEnhanced inhibitory effectWide application backgroundOrganic active ingredientsAntiviralsYellow Fever Virus InfectionCytotoxicity
The invention discloses application of Lycojaponicumin A in preparation of a drug for treating or preventing yellow fever virus infection. The Lycojaponicumin A can effectively inhabit yellow fever virus proliferation, but has low cytotoxicity, can be further developed for the preparation of drugs for treating diseases caused by yellow fever virus infection and has wide application prospect. The application of the Lycojaponicumin A in the preparation of the drug for treating the yellow fever virus infection is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high yellow fever virus inhibiting activity of the Lycojaponicumin A is unexpectedly strong, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin A has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and treatment of the yellow fever virus infection obviously.
Owner:CANVEST WUHAN BIOTECH
Application of Gypensapogenin B in medicament for treating yellow fever virus infection
ActiveCN102885835AEffective preventionEffective therapeuticOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses an application of Gypensapogenin B in the preparation of a medicament for treating or preventing yellow fever virus infection. Gypensapogenin B is capable of efficiently inhibiting the propagation of yellow fever virus, but has little toxicity for cells; and Gypensapogenin B is further capable of developing the medicament for treating diseases caused by these viruses, and has wide application prospect. The application of Gypensapogenin B in the preparation of the medicament for treating yellow fever virus infection is firstly disclosed; since the skeleton type belongs to an entirely new skeleton type and the inhibition for yellow fever virus activity is previously unimagined high without any possibility of giving out revelation by other compounds, the application has outstanding substantial characteristics; and simultaneously, the application for preventing and treating yellow fever virus infection is obviously advanced.
Owner:如东文园投资开发有限公司
Application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection
InactiveCN103251607AStrong inhibitory activitySignificant progressOrganic active ingredientsAntiviralsYellow Fever Virus InfectionCytotoxicity
The invention discloses an application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection. The Myriberine A can effectively inhibit yellow fever virus from multiplication, but has small toxicity to cells, can be further developed to prepare the medicines for treating diseases caused by virus infection and has a wide application prospect. The application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection is disclosed for the first time, a framework type belongs to a brand-new framework type, the Myriberine A has an unexpected strong effect of inhibiting the yellow fever virus activity, and the revelation possibility of other compounds cannot be generated, so the application has obvious substantive features; and moreover, the application has an obvious improved effect of preventing the yellow fever virus infection.
Owner:NANJING ZHENGLIANG MEDICAL TECH
Application of Chukrasone A in preparing medicines for treating yellow fever virus infection
InactiveCN103356651AStrong inhibitory activitySignificant progressOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses an application of Chukrasone A in preparing medicines for treating or preventing yellow fever virus infection. The Chukrasone A can effectively inhibit proliferation of yellow fever virus but is small in cytotoxicity, so that the Chukrasone A can be further developed to medicines for treating diseases caused by the virus infection, and has a wide application prospect. The use of the Chukrasone A for preparing medicines for treating yellow fever virus infection provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, and the inhibitory activity of the Chukrasone A to yellow fever virus infection is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Chukrasone A has remarkable substantial characteristics and meanwhile has remarkable progress for preventing and treating yellow fever virus infection.
Owner:丁圣雨
A kind of pharmaceutical composition containing carbamazepine and biotin and application thereof
ActiveCN108014111BReduce mortalityGood treatment effectAntiviralsHeterocyclic compound active ingredientsJapanese B Encephalitis VirusYellow Fever Virus Infection
The invention discloses a medicine composition containing carbamazepine and biotin and application thereof, and concretely relates to application of the medicine composition containing the biotin andthe carbamazepine in preparing Japanese B encephalitis virus infection medicines, zika virus infection medicines, west nile virus infection medicines, yellow fever virus infection medicines and 1-4 type dengue virus infection medicines. According to the medicine composition provided by the invention, the death rate of rats infected by Japanese B encephalitis virus can be effectively reduced; in addition, the biotin is vitamin necessary for a human body, and the carbamazepine is applied clinically for a long time and has favorable safety, so that the medicine composition containing the biotin and the carbamazepine can be further developed to be a medicine for treating flavivirus infection, and provides a new choice for clinical medication.
Owner:武汉百药联科科技有限公司
Application of traditional Chinese medicine composition in preparation of drugs for treating or preventing yellow fever virus infection
InactiveCN104922316APrevent proliferationLow toxicityAntiviralsPlant ingredientsChenopodium hybridumYellow Fever Virus Infection
The invention discloses application of a traditional Chinese medicine composition in preparation of drugs for treating or preventing yellow fever virus infection. The traditional Chinese medicine composition is prepared by extracting 15 parts of lysimachia decurrens, 18 parts of stem of climbing entada, 20 parts of chenopodium hybridum, 15 parts of desmos chinensis, 20 parts of tetrastigma hemsleyanum and 15 parts of heracleum repula and can effectively inhibit yellow fever virus multiplication, has a very small toxic effect on cells and a wide application prospect and realizes remarkable progress.
Owner:周耀忠
Application of lycojaponicumin C in preparation of medicine for treating yellow fever virus infection
InactiveCN103463067BEnhanced inhibitory effectWide application backgroundOrganic active ingredientsAntiviralsDiseaseLycojaponicumin C
The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating or preventing yellow fever virus infection. The Lycojaponicumin C can be used for effectively inhibiting the proliferation of yellow fever virus, has very low toxicity on cells, can be further developed into the medicines for treating diseases caused by the virus infection and has wide application prospects. The application of the Lycojaponicumin C in the preparation of medicines for treating the yellow fever virus infection is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on yellow fever virus, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin C has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing or treating the yellow fever virus infection.
Owner:重庆市黔江区阿蓬科技企业孵化器有限公司
Application of Gypensapogenin A in preparing drugs for treating yellow fever virus infection
ActiveCN102872057BEnhanced inhibitory effectWide application backgroundOrganic active ingredientsAntiviralsYellow Fever Virus InfectionViral infection
Owner:南通三聚知识产权服务有限公司
Application of Cordyceps sinensis in the preparation of medicines for preventing and/or treating yellow fever virus infection
ActiveCN106074627BEnhanced inhibitory effectGood effectAntiviralsPlant ingredientsDiseaseYellow Fever Virus Infection
The invention relates to pharmaceutical application of Cordyceps sinensis and provides application of Cordyceps sinensis in the preparation of drugs for preventing and / or treating yellow fever virus infections; the drugs include Cordyceps sinensis as an active ingredient and one or more pharmaceutically acceptable excipients, the Cordyceps sinensis is selected from natural Cordyceps sinensis, fermented Cordyceps sinensis mycelia and extract of the natural Cordyceps sinensis and fermented Cordyceps sinensis mycelia, and the extract is one, or a combination of any, of aqueous extract, alcohol extract, ester extract, ether extract and chloroform extract. Inhibition experiments on yellow fever virus prove that Cordyceps sinensis has good inhibition effect, and therefore it is proved that Cordyceps sinensis may be used to prevent and / or treat yellow fever virus infections and has the advantages such as significant effect, low side effect and high acting speed. Therefore, Cordyceps sinensis can be used to develop drugs for treating diseases due to yellow fever virus and has great social benefit and research value.
Owner:青海珠峰冬虫夏草工程技术研究有限公司
Application of Eryngiolide A in medicines curing yellow fever virus infection
InactiveCN103127072AStrong inhibitory activitySignificant progressOrganic active ingredientsAntiviralsDiseaseYellow Fever Virus Infection
The invention discloses application of Eryngiolide A in preparation of medicines curing or preventing yellow fever virus infection. The Eryngiolide A can effectively inhibit proliferation of the yellow fever virus, but has small toxicity to cells, can be further developed into medicines curing disease caused by the yellow fever virus, and has broad application prospect. Use of the Eryngiolide A in preparation of medicines curing the Alzheimer disease is made public for the first time, the skeleton type is completely novel, and the Eryngiolide A has an unexpectedly high yellow fever virus inhibitory activity, probability of other compounds giving any revelation for the Eryngiolide A does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently possessed in preventing and curing the yellow fever virus infection.
Owner:吴俊华
A kind of highly functional yellow fever virus human monoclonal antibody and its application
ActiveCN110343173BHigh affinityFree from attackBiological material analysisImmunoglobulins against virusesEscherichia coliAntigen
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Application of rifamycin antibiotics in preparation of drugs against yellow fever virus infections
The invention relates to the technical field of medicine, and relates to an application of rifamycin antibiotics in the preparation of drugs against yellow fever virus infections. The rifamycin antibiotics refer to semi-synthetic or synthetic antibiotics containing rifamycin derivatives, and include a variety of broad-spectrum antibiotics of the rifamycin family, the curative effect for treating bacterial infections is sure, side effects are low, and the safety is good. The application of the rifamycin antibiotics in the drugs against yellow fever virus infections is reported for the first time in the world.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Application of Lycojaponicumin A in drug for treating yellow fever virus infection
ActiveCN103446137AEnhanced inhibitory effectWide application backgroundOrganic active ingredientsAntiviralsYellow Fever Virus InfectionCytotoxicity
The invention discloses application of Lycojaponicumin A in preparation of a drug for treating or preventing yellow fever virus infection. The Lycojaponicumin A can effectively inhabit yellow fever virus proliferation, but has low cytotoxicity, can be further developed for the preparation of drugs for treating diseases caused by yellow fever virus infection and has wide application prospect. The application of the Lycojaponicumin A in the preparation of the drug for treating the yellow fever virus infection is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high yellow fever virus inhibiting activity of the Lycojaponicumin A is unexpectedly strong, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin A has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and treatment of the yellow fever virus infection obviously.
Owner:CANVEST WUHAN BIOTECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com